A multi‐stakeholder group from North America and Europe was invited to participate in the research with the Delfi method, and participants were categorized into patients/patient advocates, clinicians/researchers, U.S. payers, health technology assessors, industry representatives, or regulators. Participating patients and patient advocates represented a variety of levels of NAFLD disease severity. ELPA was represented by president Marko Korenjak. The research lasted several months and produces very important and interesting results. Outcomes of the research can contribute to decision making for regulatory, market access, and on‐market decision making. Including the core NASH COS in clinical development programs will facilitate improved comparisons and help decision-makers assess the value of new products.